Enhancing glycaemic control and promoting cardiovascular health: the therapeutic potential of trigonella foenumgraecum in diabetic patients - A systematic review and Meta-Analysis

Abstract

Background: The antidiabetic potential of fenugreek has been highlighted in past literature, and various in vitro and in vivo studies have validated its glucose-lowering effects; however, very limited data is available on its effects on diabetic patients. Objective: An updated systematic review and meta-analysis of randomised control trials, that assessed patients who were administered Fenugreek. Methods: The PRISMA guidelines, Supplemental Digital Content 1, http://links.lww.com/MS9/A361 were followed when conducting this meta-analysis. PubMed, Scopus, Google Scholar, and MEDLINE were searched from inception until June 2023, for randomised control trials that compared Fenugreek with control in patients with type 2 diabetes mellites and reported the following outcomes of interest; Fasting Blood Glucose, HbA1c and post-prandial glucose levels. The findings were presented as mean difference (MD) with 95% confidence intervals (CIs) and were pooled using a random effects model. Results: Fenugreek significantly (P<0.001) reduced the Fasting Blood Sugar (FBS), HbA1c levels and post-prandial glucose levels in diabetic patients when compared to the control. Conclusion: Among patients with Type 2 DM, our comparisons demonstrated a reduction of Fasting Blood Sugar (FBS), HbA1c levels and post-prandial glucose levels with the administration of Fenugreek seed at 2-5mg dose in powder form.